Generic drug makers Teva Pharmaceutical Industries and Dr Reddy’s Laboratories have announced the commercial launch of olanzapine tablets, a generic version of Eli Lilly antipsychotic Zyprexa.

Teva will introduce tablets in 2.5mg, 5mg, 7.5mg, 10mg, 15mg doses, while Dr Reddy’s will introduce a 20mg tablet. Both companies have been granted a 180-day period of marketing exclusivity in the US for their respective tablets.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Dr Reddy’s is supplying the 20mg version of the product as part of a commercialisation, manufacture and supply agreement agreed in April 2011.

In addition, Dr Reddy’s will launch its 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg olanzapine tablets upon expiration of the 180-day exclusivity period.

Annual sales of Zyprexa in the US stood at approximately $3.2bn as of September 2011.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Pharmaceutical Technology Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now